70190 Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices 

instruments, and the collection of 

critical data. 

This request is for a new generic 

approval to conduct information 

collections during DORIs. A three-year 

clearance is requested to ensure: (1) 

Rapid deployment of data collection 

tools and (2) timely information 

collection of vital information. Of 

particular interest is response to 

increasing trends in, or changing 

characteristics of, overdose from 

prescription drugs (with a special 

interest in opioid analgesics such as 

oxycodone or methadone; 

benzodiazepines such as alprazolam) 

and/or illicit drugs (e.g., heroin). 

Specifically, this request covers 

investigative collections with the 

following aims: (1) To understand 

sudden increases in drug use and 

misuse associated with fatal and 

nonfatal overdoses; (2) to understand 

the drivers and risk factors associated 

with those trends; and (3) to identify the 

groups most affected. This will allow 

CDC to effectively advise states on 

recommended actions to control local 

epidemics. Thus, the ultimate goals of 

these collections are to minimize 

adverse health consequences, provide 

epidemiological data collection support 

to the states and, based on the findings 

from the investigation, appropriately 

assist with implementation of 

prevention and control measures. 

Data is collected by epidemiologists, 

psychologists, medical professionals, 

subject matter experts, and 

biostatisticians. Examples of data 

collection modes that may be employed 

during DORIs include: Archival record 

abstractions and reviews, face-to-face 

interviews, telephone interviews, webbased questionnaires, and selfadministered questionnaires. 

For example, information collected 

through archival chart review from 

hospitals and medical examiners could 

include demographics, drug use history, 

reported medical and mental health 

conditions, place of overdose, place of 

death, drug paraphernalia on the scene, 

mode of administration, observers 

present, naloxone administration, 

hospital admittance, autopsy findings, 

and toxicology results. Information 

collected through interviews with 

representatives from agencies involved 

in preventing, intervening, or 

responding to drug overdose could 

include professional history, personal 

experience with drug overdose cases or 

investigations, prevention or 

intervention efforts engaged in, and 

perceptions of characteristics of, or 

changes in drug overdose cases (e.g., 

transition from opioids to heroin; 

increasing or decreasing rates). 

Collection of information from nonfatal 

overdose victims, and friends and 

family of overdose victims could 

include substance use history, 

prescription drug history, number of 

providers and pharmacies used, pain 

history, co-occurring health conditions 

(e.g., abnormal snoring indicative of 

respiratory depression), mental health 

conditions (e.g., depression, anxiety 

disorders), enrollment in drug treatment 

programs, sources of drugs, route of 

drug administration, and criminal 

history. Finally, collection of spatial 

information could be obtained through 

city, county, and state government 

agencies to determine structural and 

environmental factors associated with 

location of overdose deaths. 

Respondent type will also vary by 

investigation, but will include 

organizations typically involved in 

prevention, intervention, and response 

to drug overdose (e.g., public health, 

law enforcement authorities, health 

systems, and community organizations). 

Respondents also may include victims 

of non-fatal drug overdoses, as well as 

family and friends of victims. 

During a DORI, data is collected once, 

with the rare need for follow-up. There 

are no costs to respondents other than 

their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Drug Overdose Response Investigation Participants.Drug Overdose Response Investigation Data 

Collection Instruments.

2,700 1 .5 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–27850 Filed 11–24–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day–15–0913] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) has submitted the 

following information collection request 

to the Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. The notice for 

the proposed information collection is 

published to obtain comments from the 

public and affected agencies. 

Written comments and suggestions 

from the public and affected agencies 

concerning the proposed collection of 

information are encouraged. Your 

comments should address any of the 

following: (a) Evaluate whether the 

proposed collection of information is 

necessary for the proper performance of 

the functions of the agency, including 

whether the information will have 

practical utility; (b) Evaluate the 

accuracy of the agencies estimate of the 

burden of the proposed collection of 

information, including the validity of 

the methodology and assumptions used; 

(c) Enhance the quality, utility, and 

clarity of the information to be 

collected; (d) Minimize the burden of 

the collection of information on those 

who are to respond, including through 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology, 

e.g., permitting electronic submission of 

responses; and (e) Assess information 

collection costs. 

To request additional information on 

the proposed project or to obtain a copy 

of the information collection plan and 

instruments, call (404) 639–7570 or 

send an email to omb@cdc.gov. Written 

comments and/or suggestions regarding 

the items contained in this notice 

should be directed to the Attention: 

CDC Desk Officer, Office of Management 

and Budget, Washington, DC 20503 or 

by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 


wreier-aviles on DSK4TPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices 70191 

Proposed Project 

Evaluating Locally-Developed HIV 

Prevention Interventions for AfricanAmerican MSM in Los Angeles (OMB 

No. 0920–0913, expires 01/15/2015)— 

[Extension]—National Center for HIV/

AIDS, Viral Hepatitis, STD, and TB 

Prevention (NCHHSTP), Centers for 

Disease Control and Prevention (CDC). 

Background and Brief Description 

Data on HIV cases reported in 33 U.S. 

states with HIV reporting indicate the 

burden of HIV/AIDS is most 

concentrated in the African American 

population compared to other racial/

ethnic groups. Of the 49,704 African 

American males diagnosed with HIV 

between 2001 and 2004, 54% of these 

cases were among men who have sex 

with men (MSM). In Los Angeles 

County (LAC), the proportion of HIV/

AIDS cases among African American 

males attributable to male-to-male 

sexual transmission is even greater 

(75%). In the absence of an effective 

vaccine, behavioral interventions 

represent one of the few methods for 

reducing high HIV incidence among 

African American MSM (AAMSM). 

Unfortunately, in the third decade of the 

epidemic, very few of the available HIVprevention interventions for African 

American populations have been 

designed specifically for MSM. In fact, 

until very recently none of CDC’s 

evidence-based, HIV-prevention 

interventions had been specifically 

tested for efficacy in reducing HIV 

transmission among MSM of color. 

Given the conspicuous absence of (1) 

evidence-based HIV interventions and 

(2) outcome evaluations of existing 

AAMSM interventions, our 

collaborative team intends to address a 

glaring research gap by implementing a 

best-practices model of comprehensive 

program evaluation. 

As of November 7, 2014, 888 men 

were screened using the eligibility 

screener, 711 were eligible, and 520 

men were consented, enrolled, and 

completed the baseline assessment. 

There are a total of 227 men who 

completed 3-month follow-up and 193 

men who completed 6-month follow-up. 

Each enrolled participant completed a 

client satisfaction survey for each of the 

three intervention sessions they 

attended. Finally, twenty-two men 

consented for and completed qualitative 

interviews. There were unanticipated 

delays in getting our initial OMB 

approval and delays in enrollment 

which prevented the study from 

reaching the desired sample size of 528 

and completing data collection within 

the original 3-year timeframe. When the 

current information collection request 

(ICR) expires on January 31st, 2015, we 

will need to enroll, consent, and 

baseline approximately 10 more 

participants. To reach these additional 

10 participants, we anticipate having to 

screen approximately more 20 men. 

During this extended period, an 

additional 185 men will complete the 3- 

month assessment, 225 men will 

complete the 6-month follow-up 

questionnaires, and 14 men will consent 

for and complete the success case study 

qualitative interviews. We anticipate 

that all data collection activities will be 

completed by the end of 2015. 

The purpose of this project is to test 

in a real world setting the efficacy of an 

HIV transmission prevention 

intervention for reducing sexual risk 

among African American men who have 

sex with men in Los Angeles County. 

The intervention is a 3-session, grouplevel intervention that will provide 

participants with the information, 

motivation, and skills necessary to 

reduce their risk of transmitting or 

acquiring HIV. The intervention is being 

evaluated using baseline, 3 month and 

6 month follow up assessments. This 

project is also conducting in-depth 

qualitative interviews with a total of 36 

men in order to assess the experiences 

with the intervention, elicit 

recommendations for improving the 

intervention, and to better understand 

the factors that put young African 

American MSM at risk for HIV. 

CDC is requesting approval for a 1- 

year clearance to complete data 

collection. The data collection system 

involves screenings, limited locator 

information, contact information, 

baseline questionnaire, client 

satisfaction surveys, 3-month follow-up 

questionnaire, 6-month follow-up 

questionnaire, and case study 

interviews. An estimated 20 men will be 

screened for eligibility in order to enroll 

10 additional men to reach the desired 

sample size of 528. The baseline and 

follow up questionnaires contain 

questions about participants’ sociodemographic information, health and 

healthcare, sexual activity, substance 

use, and other psychosocial issues. The 

duration of each baseline, 3-month, and 

6-month questionnaires are estimated to 

be 60 minutes; the Success Case Study 

interviews 90 minutes; Outreach 

Recruitment Assessment 5 minutes; 

limited locator information form 5 

minutes; participant contact information 

form 10 minutes; each client satisfaction 

survey 5 minutes. 

There is no cost to participants other 

than their time. The total estimated 

annual burden hours are 459. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

respondent 

(in hours) 

Prospective Participant .................... Outreach Recruitment Assessment (screener) ............ 20 1 5/60 

Prospective Participant .................... Limited Locator Form .................................................... 20 1 5/60 

Enrolled Participant .......................... RCT Informed Consent Form ....................................... 10 1 10/60 

Enrolled Participant .......................... Participant Contact Information Form ........................... 10 1 10/60 

Enrolled Participant .......................... Baseline Questionnaire ................................................. 10 1 1 

Enrolled Participant .......................... Client Satisfaction Survey ............................................. 30 3 5/60 

Enrolled Participant .......................... 3 month follow up Questionnaire .................................. 185 1 1 

Enrolled Participant .......................... 6 month follow up Questionnaire .................................. 225 1 1 

Enrolled Participant .......................... Success Case Study Informed Consent Form ............. 14 1 10/60 

Enrolled Participant .......................... Success Case Study Interview ..................................... 14 1 1.5 


wreier-aviles on DSK4TPTVN1PROD with NOTICES
70192 Federal Register / Vol. 79, No. 227 / Tuesday, November 25, 2014 / Notices 

Leroy A. Richardson, 

Chief, Information Collection Review Office, 

Office of Scientific Integrity, Office of the 

Associate Director for Science, Office of the 

Director, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–27851 Filed 11–24–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Board of Scientific Counselors, Office 

of Public Health Preparedness and 

Response: Notice of Charter 

Amendment 

This gives notice under the Federal 

Advisory Committee Act (Pub. L. 92– 

463) of October 6, 1972, that the Board 

of Scientific Counselors, Office of Public 

Health Preparedness and Response, 

Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS), has 

amended their charter to add the Tribal 

Epidemiology Centers as a non-voting 

liaison representative. The amended 

filing date is November 5, 2014. 

For information, contact Samuel 

Groseclose, DVM, MPH, Board of 

Scientific Counselors, Office of Public 

Health and Preparedness and Response, 

Department of Health and Human 

Services, CDC, 1600 Clifton Road NE., 

Mailstop D44, Atlanta, Georgia, 30333, 

telephone (404) 639–0637, or fax (404) 

639–7977. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–27837 Filed 11–24–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP): Initial Review 

The meeting announced below 

concerns Cooperative Research 

Agreements in the area of Agricultural, 

Forestry, and Fishing Safety and Health 

Research, PAR–14–175, initial review. 

In accordance with Section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub. L. 92–463), the Centers for Disease 

Control and Prevention (CDC) 

announces the aforementioned meeting: 

Times and Dates 

1:00 p.m.–5:00 p.m., January 21, 2015 

(Closed). 

1:00 p.m.–5:00 p.m., January 22, 2015 

(Closed). 

Place: Teleconference. 

Status: The meeting will be closed to the 

public in accordance with provisions set 

forth in Section 552b(c) (4) and (6), Title 5 

U.S.C., and the Determination of the Director, 

Management Analysis and Services Office, 

CDC, pursuant to Public Law 92–463. 

Matters for Discussion: The meeting will 

include the initial review, discussion, and 

evaluation of applications received in 

response to ‘‘Agricultural, Forestry, and 

Fishing Safety and Health Research, PAR– 

14–175’’. 

Contact Person for More Information: Nina 

Turner, Ph.D., Scientific Review Officer, 

CDC/NIOSH, 1095 Willowdale Road, 

Morgantown, WV, 26506, Telephone: (304) 

285–5976. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine L. Baker, 

Director, Management Analysis and Services 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–27838 Filed 11–24–14; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Interagency Committee on Smoking 

and Health (ICSH) 

In accordance with section 10(a)(2) of 

the Federal Advisory Committee Act 

(Pub.L. 92–463), the Centers for Disease 

Control and Prevention announces the 

following meeting of the 

aforementioned committee. 

Time and Date: 9:00 a.m.–4:30 p.m., 

December 16, 2014. 

Place: Capital Hilton, Federal AB Rooms 

located at 1001 16th Street NW., Washington, 

DC 20036. Telephone: (202) 393–1000. 

Status: Open to the public, limited only by 

the space and telephone lines available. 

Participants that would like to attend in 

person are encouraged to register with the 

contact person listed below. If you will 

require a sign language interpreter, or have 

other special needs, please notify the contact 

person by 4:30 p.m. EST on December 11, 

2014. 

Limited teleconference access is also 

available. 

Login information is as follows: 

Toll Free Phone#: (800) 779–4815. 

For Public: 

Conference number: PW9452765. 

Participant passcode: 3074156. 

Participant URL: https://

www.mymeetings.com/nc/join/. 

Participants can join the event directly at: 

https://www.mymeetings.com/nc/

join.php?i=PW9452765&p=3074156&t=c. 

Purpose: The committee advises the 

Secretary, Department of Health and Human 

Services, and the Assistant Secretary for 

Health in the (a) coordination of all research 

and education programs and other activities 

within the Department and with other 

federal, state, local and private agencies, and 

(b) establishment and maintenance of liaison 

with appropriate private entities, federal 

agencies, and state and local public health 

agencies with respect to smoking and health 

activities. 

Matters for Discussion: The topic of the 

meeting is ‘‘Preventing and Reducing 

Tobacco Use in Youth and Young Adults’’ 

and the objective is to identify specific 

federal actions that can be taken to prevent 

5.6 million premature deaths from tobacco 

use among today’s youth. 

Agenda items are subject to change as 

priorities dictate. 

Contact Person for More Information: 

Substantive program information as well as 

summaries of the meeting and roster of 

committee members may be obtained from 

the Internet at www.cdc.gov/tobacco or from 

Ms. Monica L. Swann, Management and 

Program Analyst, National Center for Chronic 

Disease Prevention and Health Promotion, 

CDC, 395 E. Street SW., Washington, DC 

20024. Telephone: (202) 245–0552. 

The Director, Management Analysis and 

Services Office, has been delegated the 

authority to sign Federal Register notices 

pertaining to announcements of meetings and 

other committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Elaine Baker, 

Director, Management Analysis and Service 

Office, Centers for Disease Control and 

Prevention. 

[FR Doc. 2014–27836 Filed 11–24–14; 8:45 am] 

BILLING CODE 4163–18–P 


wreier-aviles on DSK4TPTVN1PROD with NOTICES